Docoh
Loading...

OCGN Ocugen

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Company profile

Ticker
OCGN
Exchange
CEO
Shankar Musunuri
Employees
Incorporated
Location
Fiscal year end
Former names
HISTOGENICS CORP
SEC CIK

OCGN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

7 May 21
15 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Ocugen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 44.94M 44.94M 44.94M 44.94M 44.94M 44.94M
Cash burn (monthly) (positive/no burn) (positive/no burn) 2.35M 2.03M 1.76M 1.28M
Cash used (since last report) n/a n/a 3.51M 3.04M 2.63M 1.9M
Cash remaining n/a n/a 41.43M 41.91M 42.31M 43.04M
Runway (months of cash) n/a n/a 17.6 20.6 24.0 33.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 May 21 Subramanian Sanjay Common Stock Sell Dispose S No Yes 8.183 31,000 253.67K 45,591
14 May 21 Subramanian Sanjay Common Stock Option exercise Aquire M No No 0.34 31,000 10.54K 76,591
14 May 21 Subramanian Sanjay Option Common Stock Option exercise Dispose M No No 0.34 31,000 10.54K 338,256
4 May 21 Tammara Vijay Common Stock Sell Dispose S No Yes 13.81 2,311 31.91K 0
4 May 21 Tammara Vijay Common Stock Option exercise Aquire M No No 0.565 2,311 1.31K 2,311
4 May 21 Tammara Vijay Common Stock Sell Dispose S No Yes 13.5 6,500 87.75K 0
4 May 21 Tammara Vijay Common Stock Option exercise Aquire M No No 0.51 6,500 3.32K 6,500
4 May 21 Tammara Vijay Common Stock Sell Dispose S No Yes 13.81 2,000 27.62K 0
4 May 21 Tammara Vijay Common Stock Option exercise Aquire M No No 2.94 2,000 5.88K 2,000
4 May 21 Tammara Vijay Common Stock Sell Dispose S No Yes 13.81 4,900 67.67K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 16 EXIT
Opened positions 0 4 EXIT
Closed positions 16 7 +128.6%
Increased positions 0 9 EXIT
Reduced positions 0 1 EXIT
13F shares
Current Prev Q Change
Total value 0 4.28M EXIT
Total shares 0 13.81M EXIT
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Empery Asset Management 0 $0
Largest transactions
Shares Bought/sold Change
Vanguard 0 -7.44M EXIT
BLK Blackrock 0 -5.02M EXIT
Geode Capital Management 0 -545.34K EXIT
WINTON 0 -372.09K EXIT
NTRS Northern Trust 0 -136.66K EXIT
UBS UBS Group AG - Registered Shares 0 -80.25K EXIT
Sit Investment Associates 0 -75K EXIT
JPM JPMorgan Chase & Co. 0 -65.3K EXIT
Susquehanna International 0 -22.03K EXIT
Patriot Investment Management 0 -20K EXIT

Financial report summary

?
Risks
  • The ongoing COVID-19 pandemic and actions taken in response to it may result in disruptions to our business operations, which would have a material adverse effect on our business, financial position, operating results, and cash flows.
Management Discussion
  • Research and development expense increased by $1.2 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to an increase of $0.7 million related to OCU400 preclinical activities, $0.4 million related to COVAXIN development, $0.3 million related to OCU200 preclinical activities, $0.2 million related to professional fees, and $0.1 million related to stock-based compensation expense, partially offset by a decrease of $0.5 million related to the discontinuation of OCU300 clinical trial activities in 2020.
  • General and administrative expense increased by $1.9 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to incurring $1.2 million in costs associated with obtaining an increase in the authorized shares of our common stock including proxy solicitation fees and an increase of $0.5 million related
  • to stock-based compensation expense. See Note 12 in the notes to the condensed consolidated financial statements included in this report for additional information about the increase in the authorized shares of our common stock.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abroad, accuracy, adjuvant, age, antigen, assert, asymptomatic, attract, Bharat, Biotech, BLA, Brazilian, breach, broadly, capable, cellular, certainty, Certificate, chain, China, CMC, complicate, confidence, confidentiality, congenital, contact, convenience, Council, covaxin, Delaware, demonstrated, dissolution, diverse, diversion, domain, domestic, dosed, double, durability, duration, EC, EMA, EUA, Europe, European, eventually, exhaustive, Expansion, experiencing, export, Finnerty, foreign, found, fullest, fully, furniture, global, globally, Good, Governor, harm, healthcare, Hedging, IgG, Immunoglobulin, impede, improvement, inactivated, incomplete, incorporated, Incorporation, indemnification, India, Indian, indirect, infection, inquiry, Institute, institutional, integrity, interrupt, interval, intervention, lab, Lancet, large, LCA, leasehold, leber, maintenance, Master, Medicinal, memory, mild, moderate, movement, mutant, national, Nonretirement, nucleocapsid, OMPD, overhead, overwhelmed, owner, oxygen, par, path, payroll, point, practicable, Practice, Preferred, prevent, prevention, proxy, published, quarantine, RBD, receipt, recession, reclassification, recruit, regimen, registered, relevant, rely, resource, retain, retaining, review, save, scientific, shipping, shorter, skilled, slowdown, solicitation, spectrum, spike, spread, storage, stored, stringent, strong, suggest, suggested, surge, suspension, temporary, Territory, thereon, TM, tracked, travel, uncertain, unduly, unpredictable, vaccination, vaccine, variant, Virology, vitro, waiting, wave, world, Wuhan, York
Removed: accreted, accretion, accurate, acquirer, acquisition, acting, actively, amend, amortization, amounted, announced, arise, assessed, assistance, attributable, bear, beginning, behalf, bid, bifurcated, bill, binding, bolster, case, caution, choroidal, combination, combined, comparable, comparative, concentrated, Concurrently, consecutive, constituted, consummation, contemplated, Contemporaneously, convert, corporation, coupon, covering, decreased, deemed, deficiency, delisting, depreciated, derivative, directly, director, discovering, discretionary, disposed, dividing, doubt, effected, eighteen, encounter, encountered, entirety, established, exchanged, exercised, existing, expressly, extinguish, extraordinary, eye, fact, factor, falling, favorable, feature, forma, frequently, frozen, goal, harbor, history, host, identifiable, implemented, impracticable, inability, increasing, industry, initially, intangible, July, knowledge, legally, letter, lieu, listing, Litigation, lower, lowest, manage, manner, marketed, maturity, measured, Medavate, merged, modified, month, multiplying, Musunuri, myopic, nasdaq, NeoCart, neovascularization, occlusion, occurrence, oral, owed, percentage, permit, person, placement, prepay, pro, production, pursuing, qualified, ranging, recent, recognition, recourse, recycled, redeem, redemption, reduced, Reform, regain, release, Reorganization, replaced, requirement, resale, reset, resolution, respiratory, retroactively, reverse, safe, scheduled, seek, senior, Shankar, showed, single, site, spending, structure, structured, sublicense, subscription, surviving, sweeping, symptom, terminology, thereunder, threatened, threshold, tolled, Tolling, trading, transformative, unanticipated, unforeseen, variety, vein, vi, viability, volume, warrant, written